ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,277.51
      0.80%
      US Tech 100
      18,064.80
      0.02%
      Dow Jones
      38,686.32
      1.51%
      Brent Oil
      81.295
      0.00%
      Bitcoin
      67,709.66
      -0.02%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Soligenix Inc (SNGX)

      7. Soligenix Inc (SNGX) News

      SNGX

      Soligenix (SNGX)

      Soligenix Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:SNGX
      DateTimeSourceHeadlineSymbolCompany
      05/31/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
      05/31/20247:30AMPR Newswire (US)Soligenix Announces Reverse Stock SplitNASDAQ:SNGXSoligenix Inc
      05/29/20244:05PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNGXSoligenix Inc
      05/29/20247:30AMPR Newswire (US)Soligenix Encourages Stockholders to Vote their Shares at the Annual MeetingNASDAQ:SNGXSoligenix Inc
      05/28/20244:08PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNGXSoligenix Inc
      05/24/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
      05/24/20247:30AMPR Newswire (US)Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual MeetingNASDAQ:SNGXSoligenix Inc
      05/23/20247:30AMPR Newswire (US)Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock SplitNASDAQ:SNGXSoligenix Inc
      05/22/20244:05PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNGXSoligenix Inc
      05/21/202412:35PMGlobeNewswire Inc.PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the HorizonNASDAQ:SNGXSoligenix Inc
      05/21/20247:30AMPR Newswire (US)SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX ConferenceNASDAQ:SNGXSoligenix Inc
      05/20/20247:30AMPR Newswire (US)Soligenix Encourages Stockholders to Vote Prior to Annual MeetingNASDAQ:SNGXSoligenix Inc
      05/17/20244:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
      05/17/20244:09PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNGXSoligenix Inc
      05/16/20247:30AMPR Newswire (US)Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical PracticeNASDAQ:SNGXSoligenix Inc
      05/15/20244:05PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNGXSoligenix Inc
      05/10/20244:16PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SNGXSoligenix Inc
      05/10/20244:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNGXSoligenix Inc
      05/10/20247:30AMPR Newswire (US)Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial ResultsNASDAQ:SNGXSoligenix Inc
      05/06/20247:30AMPR Newswire (US)Soligenix to Present at Upcoming ConferencesNASDAQ:SNGXSoligenix Inc
      04/25/20247:30AMPR Newswire (US)Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaNASDAQ:SNGXSoligenix Inc
      04/18/20248:30AMPR Newswire (US)Soligenix Announces Pricing of $4.75 Million Public OfferingNASDAQ:SNGXSoligenix Inc
      04/15/20247:30AMPR Newswire (US)FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus InfectionNASDAQ:SNGXSoligenix Inc
      04/11/20247:30AMPR Newswire (US)FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus InfectionNASDAQ:SNGXSoligenix Inc
      04/03/20247:30AMPR Newswire (US)Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines AgencyNASDAQ:SNGXSoligenix Inc
      03/15/20247:30AMPR Newswire (US)Soligenix Announces Recent Accomplishments and Year End 2023 Financial ResultsNASDAQ:SNGXSoligenix Inc
      02/08/20247:30AMPR Newswire (US)Soligenix Announces Formation of Behçet's Disease Medical Advisory BoardNASDAQ:SNGXSoligenix Inc
      01/25/20247:30AMPR Newswire (US)Soligenix to Present at The Microcap ConferenceNASDAQ:SNGXSoligenix Inc
      01/08/20247:30AMPR Newswire (US)FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's DiseaseNASDAQ:SNGXSoligenix Inc
      01/04/20247:30AMPR Newswire (US)Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate PsoriasisNASDAQ:SNGXSoligenix Inc
       Showing the most relevant articles for your search:NASDAQ:SNGX